Baclofen for Spasticity in Personal Injury Cases: Attorney and Patient Guide

James Wong — Founder & Pharmacist, LienScripts | February 21, 2026 | 8 min read

Baclofen is not a routine muscle relaxant — it acts at GABA-B receptors in the spinal cord and targets pathological spasticity rather than simple muscle spasm. When it appears in a PI pharmacy record, it signals a more serious neurological injury than the soft tissue cases where cyclobenzaprine is prescribed. PI attorneys should understand exactly what baclofen communicates.

Baclofen in Personal Injury: A Different Class of Muscle Relaxation

Baclofen is prescribed in personal injury cases — but it is not prescribed for the same injuries or by the same clinical reasoning as cyclobenzaprine or methocarbamol. When a physician writes a baclofen prescription for a PI patient, the drug's mechanism and approved indications communicate something specific and important: this patient has a spasticity problem rooted in the central nervous system, not simply the peripheral muscle spasm of a cervical or lumbar strain.

For PI attorneys who encounter baclofen in the pharmacy record, understanding its mechanism, its clinical indications, its titration requirements, and its discontinuation risks is essential to accurately representing the injury severity it reflects. This guide covers all of those elements.

GABA-B Receptor Mechanism: How Baclofen Works

Baclofen is a GABA-B receptor agonist — it activates GABA-B receptors in the spinal cord to inhibit the pathologically elevated excitatory signaling that drives spasticity.

To understand why this matters, consider the physiology of spasticity:

After injury to the spinal cord, brain (TBI), or central motor pathways, the normal inhibitory control over motor neuron activity is disrupted. Upper motor neuron injury removes the descending inhibitory signals that keep motor neurons from firing excessively. The result is spasticity — involuntary, sustained, often painful muscle contractions driven by disinhibited spinal reflex arcs. Spasticity is qualitatively and mechanistically different from the acute protective muscle spasm that follows a soft tissue injury.

Baclofen targets this pathological spinal mechanism directly. By activating GABA-B receptors at the presynaptic level, baclofen suppresses the release of excitatory neurotransmitters (glutamate, aspartate, substance P) from sensory afferent fibers entering the spinal cord. It also activates postsynaptic GABA-B receptors in the spinal cord, hyperpolarizing motor neurons and reducing their excitability. The result is reduced spasticity — reduced velocity-dependent resistance to passive movement, reduced involuntary spasms, and reduced spasm-related pain.

This is fundamentally different from cyclobenzaprine's anticholinergic mechanism (brainstem motor neuron activity reduction), methocarbamol's general CNS depression (polysynaptic transmission quieting), and tizanidine's alpha-2 agonism (spinal excitatory neurotransmitter release inhibition). Baclofen operates at a more targeted GABA-B level in the spinal cord.

[!KEY] Baclofen acts on GABA-B receptors to suppress pathologically disinhibited spinal motor neuron firing — the mechanism underlying spasticity from upper motor neuron injury. Its presence in a PI pharmacy record signals upper motor neuron involvement from spinal cord injury, TBI, or severe neurological insult. This is a materially different clinical picture than the peripheral muscle spasm that cyclobenzaprine and methocarbamol address.

FDA Approval and Clinical Indications in PI

Baclofen's FDA-approved indications are spasticity from multiple sclerosis and spasticity from spinal cord disease or injury. Both indications are neurological — upper motor neuron conditions where descending inhibitory control is disrupted.

In the PI context, baclofen is prescribed for:

Spinal Cord Injury (SCI)

SCI — whether complete or incomplete — disrupts descending motor pathways, producing spasticity below the level of injury. Baclofen is the first-line pharmacological treatment for SCI-associated spasticity, prescribed to reduce involuntary spasms, manage spasm-related pain, and improve the patient's ability to participate in rehabilitation.

Traumatic Brain Injury (TBI)

TBI damages upper motor neuron pathways, producing spasticity affecting the extremities. Baclofen is used for TBI-associated spasticity, particularly in moderate-to-severe TBI cases where spasticity is a significant functional complication.

Severe Cervical Myelopathy

When cervical disc herniation or traumatic cervical injury results in spinal cord compression (myelopathy) rather than simply nerve root compression (radiculopathy), the upper motor neuron damage produces spasticity in the extremities. A PI patient with a traumatic C5-C6 herniation that compressed the spinal cord — not merely the nerve root — may have myelopathic spasticity requiring baclofen.

Refractory Muscle Spasm Not Responding to Standard Agents

In severe soft tissue and orthopedic injury cases where standard muscle relaxants (cyclobenzaprine, methocarbamol) have been tried and found insufficient, baclofen is sometimes prescribed off-label for the refractory spasm component. This off-label use is less common than its spasticity indications but does appear in PI records.

Oral vs. Intrathecal Baclofen: A Critical Distinction

Baclofen is available in two fundamentally different delivery systems, and PI attorneys should understand the clinical difference:

Oral Baclofen

Oral baclofen tablets (5 mg, 10 mg, 20 mg) are the standard outpatient form. The drug is absorbed from the GI tract, crosses the blood-brain barrier, and reaches GABA-B receptors in the spinal cord through systemic circulation. The challenge with oral baclofen is that the dose required to achieve adequate spinal cord concentrations frequently produces significant CNS side effects — sedation, cognitive dulling, fatigue, and weakness — because the drug must achieve relatively high systemic levels to achieve therapeutic spinal cord levels.

Oral baclofen appears in PI outpatient pharmacy records for mild-to-moderate spasticity management.

Intrathecal Baclofen (ITB)

For patients with severe spasticity that cannot be adequately controlled with oral baclofen at tolerable doses, intrathecal baclofen (delivered directly into the cerebrospinal fluid via a surgically implanted pump) achieves effective spinal concentrations at a fraction of the systemic dose required orally — dramatically reducing systemic side effects while providing superior spasticity control.

Intrathecal baclofen pump placement is a surgical procedure. A PI patient who has progressed to ITB pump implantation has documented severe, refractory spasticity — a significant injury severity marker. The pump requires ongoing programming, refills (the reservoir must be filled with baclofen via transcutaneous injection every 1–6 months), and monitoring visits.

For PI attorneys, ITB pump documentation represents a major durable medical equipment component of the damages picture — the pump implantation surgery, the device itself, and the ongoing pharmacy cost of the intrathecal baclofen refills are all recoverable economic damages.

[!KEY] Intrathecal baclofen pump placement is not a routine medication management step — it represents a clinical determination that the patient's spasticity is severe, refractory to oral management, and requires surgical implantation of a drug delivery system. A PI case involving an ITB pump is a serious injury case with significant long-term care needs that extend well beyond the standard demand package framing.

Dosing Titration Requirements: Why Careful Management Matters

Oral baclofen requires careful dose titration — gradual dose increases over weeks — because both the therapeutic window and the side effect profile are dose-sensitive.

Starting dose: 5 mg three times daily (TID), increasing by 5 mg per dose every 3 days as tolerated, up to a maximum of 80 mg/day (20 mg QID).

Why titration is required:

1. Sedation and weakness at higher doses are the primary dose-limiting side effects — increasing too quickly produces intolerable CNS depression.
2. Individual variability is significant — patients reach effective and tolerable doses at very different points in the titration range.
3. Efficacy assessment requires adequate time at each dose level before concluding the dose is insufficient.

The titration requirement means that baclofen prescribing generates a series of prescriptions at escalating doses over a multi-week period — and each prescribing encounter is a documented clinical touchpoint establishing ongoing physician oversight and active spasticity management.

Abrupt Discontinuation Risks: Seizures and Hallucinations

The most clinically critical fact about baclofen — for both patient safety and PI case documentation — is the danger of abrupt discontinuation.

Patients who have been on regular baclofen therapy and stop taking it suddenly (whether due to running out of medication, insurance denial, or intentional discontinuation) are at risk for a serious withdrawal syndrome including:

• Seizures (potentially life-threatening)
• Hallucinations
• Severe rebound spasticity
• Hyperthermia
• Rhabdomyolysis (muscle breakdown)
• Multi-organ failure in severe cases

This discontinuation risk is not theoretical — baclofen withdrawal deaths have been documented in the literature, particularly following abrupt pump failure in intrathecal baclofen patients, but also following sudden cessation of oral therapy.

For PI attorneys, this discontinuation risk has several practical implications:

1. Insurance denial of baclofen is a patient safety issue — an insurer who denies baclofen refill coverage, causing a PI patient to run out of the medication, has created a withdrawal risk that extends the medical harm narrative.
2. Pharmacy lien coverage prevents dangerous interruption — ensuring continuous baclofen dispensing under the lien eliminates the risk of denial-driven discontinuation.
3. Documentation of ongoing baclofen use establishes that discontinuation is not clinically appropriate without careful tapering — supporting long-term treatment duration claims.

[!SOURCE] Dario A, Tomei G. "A benefit-risk assessment of baclofen in severe spinal spasticity." Drug Safety, 2004;27(11):799–818. https://pubmed.ncbi.nlm.nih.gov/15350150/ — This review documents baclofen's clinical role in severe spasticity, its titration requirements, and the clinically significant risks of abrupt discontinuation referenced in this article.

Distinction From Standard Muscle Relaxants: Why It Matters in PI

The most important conceptual point for PI attorneys is understanding how baclofen differs from the standard muscle relaxants that dominate most PI pharmacy records:

When baclofen appears in a PI pharmacy record, the injury severity signal is qualitatively different from a cyclobenzaprine prescription. The treating physician has determined that the patient has a spasticity syndrome — upper motor neuron dysfunction — that requires GABA-B-mediated spinal cord intervention. This is a neurologically significant finding that attorneys should flag and address explicitly in the demand narrative.

The Pharmacist's Role in Safe Baclofen Dispensing

Given baclofen's serious discontinuation risks and its dose-sensitive side effect profile, the dispensing pharmacist plays an active patient safety role:

• Monitoring refill timing to ensure the patient does not run out of medication between prescriptions
• Checking for drug interactions — baclofen's CNS depression can be dangerous when combined with opioids, benzodiazepines, or other CNS depressants common in PI treatment regimens
• Counseling patients on discontinuation risks — patients must understand that stopping baclofen without physician guidance is dangerous
• Coordinating with the prescribing physician when a patient appears to be approaching running out of medication or when insurance denial threatens supply
• Documenting all clinical consultations in the dispensing record

For PI attorneys, the pharmacist's documentation of these safety-oriented interactions is additional clinical documentation supporting active medication management throughout the treatment course.

Pharmacy Lien Coverage for Baclofen

Baclofen — both oral and the pharmacy component of intrathecal pump refills — is covered under pharmacy lien for PI patients as a prescription medication dispensed pursuant to a physician's order for injuries attributable to the incident. The full treatment course is captured in the dispensing record and included in the MERIT.

For serious PI cases involving SCI, TBI, or myelopathy, baclofen may be a long-term, potentially indefinite medication — not a short-course acute treatment. The long-term dispensing timeline in the pharmacy record directly supports claims for future medical expenses and long-term care needs in the demand package.

Pharmacy lien coverage is particularly critical for baclofen patients because insurance denial mid-course creates not just an inconvenience but a genuine patient safety risk from withdrawal. Continuous lien-based coverage eliminates this risk.

[!SOURCE] FDA Prescribing Information for Baclofen Tablets (Lioresal). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017078s068lbl.pdf — FDA label documenting baclofen's mechanism, FDA-approved spasticity indications, dosing titration requirements, and abrupt discontinuation warnings referenced in this article.

Documentation in Serious Injury Demand Packages

When preparing demand packages in SCI, TBI, or myelopathy PI cases, baclofen documentation should include:

1. Link to the neurological injury — baclofen prescribing should be connected to the medical records establishing the upper motor neuron diagnosis (spinal cord MRI findings, neurology consultation notes documenting spasticity).
2. Titration record — the escalating dose history from the pharmacy records documents the clinical progression of spasticity management.
3. Document the discontinuation warning — noting that baclofen cannot be stopped without careful tapering supports the long-duration treatment claim and establishes that this is not a discretionary medication.
4. For ITB pump patients — include the pump implantation surgical records, the ongoing refill documentation, and the programming visit history as components of the long-term care damages calculation.
5. MERIT itemization — the full dispensing record from first fill through current treatment provides the chronological backbone for the medication damages section.

Related Resources

• Spinal Cord Injury Medications and Long-Term Pharmacy Lien
• Concussion and TBI Medication Guide and Pharmacy Lien
• Cyclobenzaprine vs. Tizanidine: Muscle Relaxant Comparison for PI Cases
• Pharmacy Lien Support for Neurology